What is the Fiscal Year for Aptose Biosciences?
Date: November 13, 2026
Aptose Biosciences's current fiscal year starts on January 1, 2025, and ends on December 31, 2025. Their current quarter is Q4, which ends on January 1, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2025
Fiscal Year End
December 31, 2025
Current Quarter
Q4
Current Quarter End
January 1, 2026
Quarterly Breakdown
Q1
Jan 1, 2025 – Mar 31, 2025
Q2
Apr 1, 2025 – Jun 30, 2025
Q3
Jul 1, 2025 – Sep 30, 2025
Q4
Oct 1, 2025 – Dec 31, 2025
Company Information
Headquarters
San Diego, California
Industry
Biotechnology Research
Stock Symbol
APTO
Website
https://aptose.comDescription
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments. CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies. APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Aptose Biosciences and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.